JonesResearch analyst Catherine Novack downgraded Gritstone to Hold from Buy without a price target While the Phase 2 GRANITE data were directionally positive, Jones did not see a significant benefit in the overall population, and it does not have confidence in topline results at this time, the analyst tells investors in a research note. The firm cites lower confidence in Gritstone’s neoantigen vaccine programs for the downgrade.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRTS:
- Gritstone downgraded at B. Riley on near-term balance sheet uncertainty
- Gritstone downgraded to Neutral from Buy at B. Riley
- Gritstone downgraded to Neutral from Buy at H.C. Wainwright
- Gritstone downgraded to Market Perform from Outperform at JMP Securities
- Gritstone announces interim GRANITE study data
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue